Phlebologie 2018; 47(05): 261-264
DOI: 10.12687/phleb2437-5-2018
Kasuistik – Case report
Georg Thieme Verlag KG Stuttgart · New York

IgA antiphospholipid syndrome – a rare clinical variant

Article in several languages: deutsch | English
S. Lutze
1   Klinik- und Poliklinik für Haut-und Geschlechtskrankheiten, Universitätsmedizin Greifswald, Greifswald
,
M. Ahmed
1   Klinik- und Poliklinik für Haut-und Geschlechtskrankheiten, Universitätsmedizin Greifswald, Greifswald
,
W. Konschake
1   Klinik- und Poliklinik für Haut-und Geschlechtskrankheiten, Universitätsmedizin Greifswald, Greifswald
,
G. Daeschlein
1   Klinik- und Poliklinik für Haut-und Geschlechtskrankheiten, Universitätsmedizin Greifswald, Greifswald
,
M. Jünger
1   Klinik- und Poliklinik für Haut-und Geschlechtskrankheiten, Universitätsmedizin Greifswald, Greifswald
› Author Affiliations
Further Information

Publication History

Eingegangen: 09 July 2018

Angenommen: 18 July 2018

Publication Date:
14 September 2018 (online)

Summary

IgA subtype antiphospholipid syndrome is a variant within the antiphospholipid syndrome group. It is also associated with a significantly increased risk of thrombembolic complications, as is the IgG antiphospholipid syndrome, IgM isotype. The clinical picture on the skin is varied, ranging from livedo race-mosa to ulcers cruris and disseminated vasculitic lesions. Especially the vasculitic changes can best be explained by the properties of the immunoglobulin subtype. The addition of IgA antibodies and a skin biopsy is often helpful for further diagnosis and differentiation of other differential diagnoses.

 
  • Literatur

  • 1 Hughes JP, Stovin PGI.. Segmental pulmonary artery aneurysms with peripheral venous thrombosis.. Br J Dis Chest 1959; 53: 19-27 doi:10.1016/S0007–0971(59)80106–6
  • 2 Cervera R.. Antiphospholipid sydrome.. In: Thrombosis Research 2017; 151: 43-S47 DOI: 10.2016/S0049–3848(17)30066-X.
  • 3 Gómez-Puerta JA, Cervera R.. Diagnosis and classification of the antiphospholipid syndrome.. In: Journal of autoimmunity 2014; 48–49: 20-25 DOI:10.1016/j.jaut.2014.01.006.
  • 4 Cervera R, Khamashta MA, Shoenfeld Y, Camps MT, Jacobsen S, Kiss E. et al. Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients.. Ann Rheum Dis 2009; 68: 1428-1432.
  • 5 Cervera R, Serrano R, Pons-Estel GJ, Ceberio-Hualde L, Shoenfeld Y, de Ramón E. et al. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients.. Ann Rheum Dis 2015; 74: 1011-1018.
  • 6 Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC. et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop.. Arthritis Rheum 1999; 42: 1309-1311.
  • 7 Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).. J Thromb Haemost 2006; 4: 295-306.
  • 8 14th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends Doruk Erkan a, Cassyanne L. Aguiar a, Danieli Andrade b, Hannah Cohen c,d, Maria J. Cuadrado e, Adriana Danowski f, Roger A. Levy g, Thomas L. Ortel h, Anisur Rahman c,d, Jane E. Salmon a, Maria G. Tektonidou i, Rohan Willis j, Michael D. Lockshin a
  • 9 Sunderkötter C, Pappelbaum K, Ehrchen J.. Hautarzt 2015; 66: 589. https://doi.org/10.1007/s00105–015–3661–6
  • 10 Davin J-C.. Henoch-Schonlein purpura nephritis. Pathophysiology, treatment, and future strategy.. Clinical journal of the American Society of Nephrology, CJASN 2011; 6 (03) 679-689 DOI: 10.2215/CJN.06710810.